How Do CGRP Monoclonal Antibodies Work?

Calcitonin gene-related peptide (CGRP) monoclonal antibodies are drugs used for preventing episodic migraines.

CGRP is a protein that is released around the brain. When released in excess, CGRP causes intense inflammation in the coverings of the brain (meninges). Excess CGRP release in the brain aggravates the pain of a migraine attack.

CGRP monoclonal antibodies bind to CGRP receptors and block the binding of CGRP, thereby preventing the inflammation of meninges and controlling migraine pain.

CGRP monoclonal antibodies are given via the intravenous route for preventive treatment of migraines.

CGRP monoclonal antibodies are well-tolerated. Most people do not seem to have significant side effects other than some pain at the injection site. However, few may report the following side effects:

• Constipation
• Muscle spasms
• Rash
• Hypersensitivity
• Mouth ulcers
• Hypertension

The information contained herein is not intended to cover all possible side effects, precautions, warnings, drug interactions, allergic reactions, or adverse effects. Check with your doctor or pharmacist to make sure these drugs do not cause any harm when you take them along with other medicines. Never stop taking your medication and never change your dose or frequency without consulting your doctor.

Generic and brand names of CGRP monoclonal antibodies include:

• Aimovig
• Ajovy
• Emgality
• Eptinezumab
• Eptinezumab-JJMR
• Erenumab
• Fremanezumab
• Fremanezumab-VFRM
• Galcanezumab
• Galcanezumab-GNLM
• Vyepti